This is Part 2 in a three-part series on patient-centered outcomes. (Check out Part 1 and Part 3). A personalized medicine approach to clinical...

This is Part 1 in a three-part series on patient-centered outcomes. (Check out Part 2 and Part 3). In different regulatory and research settings...

Looking back on papers published in high profile journals over the years, the path to publication has become ever more involved. The number of...

Core labs at academic institutes lower the barrier to expensive technology and give people access to techniques outside their field of expertise...

Targeted based drug discovery has been a mainstay of pharmaceutical pipelines for the last 20 years. Identifying and validating novel drug...

Steve Blank wrote an excellent 3 part blog series last week. We covered Part 1 which described the challenges Life Science companies face in...

The US giant has been given a virtual outsourcing platform for Pfizer scientists called the MXIS (Market Exchange for Innovative Services) via...

In a recent case study by Scientist, Joe Payne told us of this rule of thumb. “If you need the compound in 3 hours, make it in house; 3 days...

Interesting news for those thinking about personalized medicine and drug development: children born to mothers after bariatric gastrointestinal...

Life science companies are known to be one of the most expensive and difficult to start up. We look for an answer as to why in an excellent article...